

Dua'a Ghazi Farah	
Telephone	(Mobile): +962 797967167
Email	Dfarah@zu.edu.jo

QUALIFICATIONS	<p>(2017-2022): Ph.D. in pharmaceutical sciences from the University of Jordan with a GPA of (3.85/4 [Excellence]). Minor: Pharmaceutics and pharmaceutical analysis Thesis: Insulin Detemir: potential drug interactions and efforts to prolong action.</p> <p>(2013-2016): Master in pharmaceutical sciences from the University of Jordan with a GPA of (3.75/4 [Excellence]). Thesis: Effect of organic anions on the intestinal absorption of metformin HCl</p> <p>(2006 – 2012): B.Sc. in Doctor of Pharmacy from the University of Jordan with a GPA of (3.81/4 [Excellence]).</p>
WORK EXPERIENCE	<p>(2022-present): Assistant professor at the Faculty of Pharmacy/ Zarqa University</p> <p>(2016-2019): Lecturer at the Faculty of Pharmacy/ Zarqa University</p> <p>(2012-2015): Teaching assistant at the faculty of Pharmacy/ Zarqa University</p>
PUBLICATIONS	<ul style="list-style-type: none"> Hamdan, I. I., Dua'a, G. H., Khalil, E. A., Mansour, R. S., & Abdel-Halim, H. (2022). Interaction of esomeprazole with insulin detemir and human albumin: A potential cause of hypoglycemia. Biophysical Chemistry, 285, 106809. Farah, D., Khalil, E., Mansour, R., & Hamdan, I. (2022). Development and Validation of a Stability-indicating HPLC Method for Determination of Insulin Detemir and Preservatives in their Injection Products. Analytical and Bioanalytical Chemistry Research, 9(1), 85-99 Hamdan, I. I., Farah, D. A. G., & Abu-Dahab, R. (2020). Chromatographic behavior and analytical method development for metformin HCl: application to permeation studies through caco-2 cells. Acta poloniae pharmaceutica, 77(1), 11-21. Elayeh, E., Akour, A., Yousef, A., Farah, D. A., Hamaly, M., & Basheti, I. (2014). Osteoporosis amongst Jordanians: effect of pharmacist-directed brochure education on people's knowledge. Tropical Journal of Pharmaceutical Research, 13(12), 2101-2108. Suyagh M., Farah D., Abu Farha R. Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharmaceutical Journal. 2014; 113:21–220.